Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

cs and clinical benefit has not been established.

Safety Assessment

The majority of adverse events reported in this study were mild to moderate in severity. The most frequently reported adverse events for VYVANSE were insomnia (8 percent), decreased appetite (6 percent), anorexia (4 percent) and upper respiratory tract infection (2 percent); for Adderall XR they were decreased appetite (4 percent), upper abdominal pain (4 percent), insomnia (2 percent), upper respiratory tract infection (2 percent) and vomiting (2 percent).

VYVANSE is currently approved in the United States for the treatment of ADHD in children aged 6 to 12 years.

Additional information about VYVANSE and Full Prescribing Information are available at http://www.vyvanse.com.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. The disorder is also estimated to affect 8.1 percent of adults, or approximately 9.2 million adults across the U.S. based on a retrospective survey of adults aged 18 to 44, projected to the full U.S. adult population. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... 31, 2014 Adventist Health System, ... U.S. including Florida Hospital Tampa, Florida Hospital Carrollwood, ... Hospital North Pinellas, Florida Hospital Wesley Chapel, Florida ... Florida Hospital Heartland Medical Center Lake Placid and ... list of Most Wired Hospitals and Health Systems, ...
(Date:7/31/2014)... Peninsula, MI (PRWEB) July 31, 2014 The ... preparation of the upcoming harvest. And, to celebrate, folks are ... Saturday and Sunday, September 6 and 7, 2014 along the ... festivities is an optional walk or run through the vineyards ... Winery in Suttons Bay. A unique course between rows of ...
(Date:7/31/2014)... July 31, 2014 Weblify has finally been ... years of development and testing. The result is a ... in as little as 5 minutes without knowing any HTML ... review , Shane Michaels, an SEO expert, agrees that this ... “I’ve seen a lot of web site builders out there, ...
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... of its faculty, Anthony Le Donne and Peter J. ... Also new to United is a Director of ... August 1. , Anthony Le Donne, Assistant Professor ... United Kingdom. He teaches New Testament, Second Temple Judaism, ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Growing Seminary Welcomes New Faculty 2
... alternative remedies more likely to misuse prescribed drugs, suffer ... Many asthma patients who use herbal remedies experience increased ... shows. , Researchers followed 326 asthma patients for 33 ... herbal remedies and used prescribed inhaled corticosteroids (ICS) less ...
... Insurance Companies Amend Policy on Radioembolization Coverage , OTTAWA, ... global leader in providing products and services for medical ... largest health insurers in the United States ... liver cancer, which includes the use of MDS Nordion,s ...
... , ... costs, boost efficiency , SILVER SPRING, Md. , ... Administration today issued guidance on Bayesian statistical methods in the ... result in less costly and more efficient patient studies. , ...
... recognized as a complication of erosive esophagitis and is ... A research team from Yokohama City University School of ... might be useful for identifying a subgroup with a ... study will be published on January 28, 2010 in ...
... Whitewater Courses and ... challenge participants with hard-to-hear truths about the responsibilities of developers who promote atop the ... designers, engineers and river scientist will take place May 24-27, 2010 in Salida, CO. ... (PRWEB) March 3, 2010 -- ...
... sugar of children, teens stable longer , THURSDAY, Feb. 4 ... teenagers with type 1 diabetes could benefit by using an ... blood sugar levels during sleep and help them control their ... issue of The Lancet , examined use of an ...
Cached Medicine News:Health News:Herbals Not the Answer for Asthma, Study Shows 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 3Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 4Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 2Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 3Health News:Hard Green Truths - Keynotes Suggest New Value Propositions for River Park Leaders 2Health News:Artificial Pancreas Helps Type 1 Diabetics During Sleep 2
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: